1
|
Cimoli G, Bagnasco L, Pescarolo MP, Avignolo C, Melchiori A, Pasa S, Biasotti B, Taningher M, Parodi S. Signaling Proteins as Innovative Targets for Antineoplastic Therapy: Our Experience with the Signaling Protein C-myc. Tumori 2018. [DOI: 10.1177/030089160108700636] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Guido Cimoli
- Department of Oncology Biology and Genetics, University of Genoa; National Cancer Research Institute of Genoa, Italy
| | - Luca Bagnasco
- Department of Oncology Biology and Genetics, University of Genoa; National Cancer Research Institute of Genoa, Italy
| | - Maria Pia Pescarolo
- Department of Oncology Biology and Genetics, University of Genoa; National Cancer Research Institute of Genoa, Italy
| | - Carlo Avignolo
- Department of Oncology Biology and Genetics, University of Genoa; National Cancer Research Institute of Genoa, Italy
| | - Antonella Melchiori
- Department of Oncology Biology and Genetics, University of Genoa; National Cancer Research Institute of Genoa, Italy
| | - Stefania Pasa
- Department of Oncology Biology and Genetics, University of Genoa; National Cancer Research Institute of Genoa, Italy
| | - Barbara Biasotti
- Department of Oncology Biology and Genetics, University of Genoa; National Cancer Research Institute of Genoa, Italy
| | - Maurizio Taningher
- Department of Oncology Biology and Genetics, University of Genoa; National Cancer Research Institute of Genoa, Italy
| | - Silvio Parodi
- Department of Oncology Biology and Genetics, University of Genoa; National Cancer Research Institute of Genoa, Italy
| |
Collapse
|
2
|
Forina M, Oliveri P, Bagnasco L, Simonetti R, Casolino MC, Nizzi Grifi F, Casale M. Artificial nose, NIR and UV-visible spectroscopy for the characterisation of the PDO Chianti Classico olive oil. Talanta 2015; 144:1070-8. [PMID: 26452929 DOI: 10.1016/j.talanta.2015.07.067] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2015] [Revised: 07/14/2015] [Accepted: 07/27/2015] [Indexed: 10/23/2022]
Abstract
An authentication study of the Italian PDO (Protected Designation of Origin) olive oil Chianti Classico, based on artificial nose, near-infrared and UV-visible spectroscopy, with a set of samples representative of the whole Chianti Classico production area and a considerable number of samples from other Italian PDO regions was performed. The signals provided by the three analytical techniques were used both individually and jointly, after fusion of the respective variables, in order to build a model for the Chianti Classico PDO olive oil. Different signal pre-treatments were performed in order to investigate their importance and their effects in enhancing and extracting information from experimental data, correcting backgrounds or removing baseline variations. Stepwise-Linear Discriminant Analysis (STEP-LDA) was used as a feature selection technique and, afterward, Linear Discriminant Analysis (LDA) and the class-modelling technique Quadratic Discriminant Analysis-UNEQual dispersed classes (QDA-UNEQ) were applied to sub-sets of selected variables, in order to obtain efficient models capable of characterising the extra virgin olive oils produced in the Chianti Classico PDO area.
Collapse
Affiliation(s)
- M Forina
- University of Genoa, Department of Pharmacy, Via Brigata Salerno 13, I-16147 Genoa, Italy
| | - P Oliveri
- University of Genoa, Department of Pharmacy, Via Brigata Salerno 13, I-16147 Genoa, Italy
| | - L Bagnasco
- University of Genoa, Department of Pharmacy, Via Brigata Salerno 13, I-16147 Genoa, Italy
| | - R Simonetti
- University of Genoa, Department of Pharmacy, Via Brigata Salerno 13, I-16147 Genoa, Italy
| | - M C Casolino
- University of Genoa, Department of Pharmacy, Via Brigata Salerno 13, I-16147 Genoa, Italy
| | - F Nizzi Grifi
- Consorzio Olio DOP Chianti Classico, Via Scopeti 155, I-50026 San Casciano in Val di Pesa, Florence, Italy
| | - M Casale
- University of Genoa, Department of Pharmacy, Via Brigata Salerno 13, I-16147 Genoa, Italy.
| |
Collapse
|
3
|
Grozio A, Gonzalez VM, Millo E, Sturla L, Vigliarolo T, Bagnasco L, Guida L, D'Arrigo C, De Flora A, Salis A, Martin EM, Bellotti M, Zocchi E. Selection and characterization of single stranded DNA aptamers for the hormone abscisic Acid. Nucleic Acid Ther 2013; 23:322-31. [PMID: 23971905 PMCID: PMC3760064 DOI: 10.1089/nat.2013.0418] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The hormone abscisic acid (ABA) is a small molecule involved in pivotal physiological functions in higher plants. Recently, ABA has been also identified as an endogenous hormone in mammals, regulating different cell functions including inflammatory processes, stem cell expansion, insulin release, and glucose uptake. Aptamers are short, single-stranded (ss) oligonucleotidesable to recognize target molecules with high affinity. The small size of the ABA molecule represented a challenge for aptamer development and the aim of this study was to develop specific anti-ABA DNA aptamers. Biotinylated abscisic acid (bio-ABA) was immobilized on streptavidin-coated magnetic beads. DNA aptamers against bio-ABA were selected with 7 iterative rounds of the systematic evolution of ligands by exponential enrichment method (SELEX), each round comprising incubation of the ABA-binding beads with the ssDNA sequences, DNA elution, electrophoresis, and polymerase chain reaction (PCR) amplification. The PCR product was cloned and sequenced. The binding affinity of several clones was determined using bio-ABA immobilized on streptavidin-coated plates. Aptamer 2 and aptamer 9 showed the highest binding affinity, with dissociation constants values of 0.98 ± 0.14 μM and 0.80 ± 0.07 μM, respectively. Aptamers 2 and 9 were also able to bind free, unmodified ABA and to discriminate between different ABA enantiomers and isomers. Our findings indicate that ssDNA aptamers can selectively bind ABA and could be used for the development of ABA quantitation assays.
Collapse
Affiliation(s)
- Alessia Grozio
- Department of Experimental Medicine, Section of Biochemistry, University of Genova, Genova, Italy
| | - Victor M. Gonzalez
- Departamento de Bioquímica-Investigación, IRYCIS-Hospital Ramón y Cajal, Madrid, Spain
| | - Enrico Millo
- Center of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy
| | - Laura Sturla
- Center of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy
| | - Tiziana Vigliarolo
- Department of Experimental Medicine, Section of Biochemistry, University of Genova, Genova, Italy
| | - Luca Bagnasco
- Department of Internal Medicine, University of Genova, Genova, Italy
| | - Lucrezia Guida
- Center of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy
| | - Cristina D'Arrigo
- Institute for Macromolecular Studies, National Research Council, Genova, Italy
| | - Antonio De Flora
- Center of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy
| | - Annalisa Salis
- Center of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy
| | - Elena M. Martin
- Departamento de Bioquímica-Investigación, IRYCIS-Hospital Ramón y Cajal, Madrid, Spain
| | - Marta Bellotti
- Center of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy
| | - Elena Zocchi
- Center of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy
| |
Collapse
|
4
|
Ciociano N, Saullo F, Pacillo M, Romano F, Bagnasco L. GRP-020 Analysis of Italian Hospital Pharmacist Activities to Prevent LASA Drug Errors in Treatment: First Results. Eur J Hosp Pharm 2013. [DOI: 10.1136/ejhpharm-2013-000276.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
5
|
Ponassi R, Biasotti B, Tomati V, Bruno S, Poggi A, Malacarne D, Cimoli G, Salis A, Pozzi S, Miglino M, Damonte G, Cozzini P, Spyrakis F, Campanini B, Bagnasco L, Castagnino N, Tortolina L, Mumot A, Frassoni F, Daga A, Cilli M, Piccardi F, Monfardini I, Perugini M, Zoppoli G, D’Arrigo C, Pesenti R, Parodi S. Erratum to Ponassi R, et al. Cell Cycle Volume 7, Issue 20; pp. 3211-24. Cell Cycle 2012. [PMCID: PMC3478321 DOI: 10.4161/cc.22288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Raffaella Ponassi
- Department of Oncology, Biology and Genetics; University of Genoa; Genoa, Italy
- Laboratory of Experimental Oncology; National Cancer Institute (IST); Genoa, Italy
| | - Barbara Biasotti
- Department of Oncology, Biology and Genetics; University of Genoa; Genoa, Italy
- Laboratory of Experimental Oncology; National Cancer Institute (IST); Genoa, Italy
| | - Valeria Tomati
- Department of Oncology, Biology and Genetics; University of Genoa; Genoa, Italy
- Laboratory of Experimental Oncology; National Cancer Institute (IST); Genoa, Italy
| | - Silvia Bruno
- Department of Experimental Medicine; Section of Human Anatomy; University of Genoa; Genoa, Italy
| | - Alessandro Poggi
- Laboratory of Immunology; National Cancer Institute (IST); Genoa, Italy
| | - Davide Malacarne
- Laboratory of Experimental Oncology; National Cancer Institute (IST); Genoa, Italy
| | - Guido Cimoli
- Tecan Italia S.r.l.; Cernusco Sul Naviglio (MI); Italy
| | - Annalisa Salis
- Department of Experimental Medicine; Biochemistry section c/o Center of Excellence for Biomedical Research; Genoa, Italy
| | - Sarah Pozzi
- Department of Hemato-Oncology; S. Martino Hospital; Genoa, Italy
| | | | - Gianluca Damonte
- Department of Experimental Medicine; Biochemistry section c/o Center of Excellence for Biomedical Research; Genoa, Italy
| | - Pietro Cozzini
- Biochemistry and Molecular Biology; University of Parma; Parma, Italy
| | | | - Barbara Campanini
- Biochemistry and Molecular Biology; University of Parma; Parma, Italy
| | - Luca Bagnasco
- Department of Oncology, Biology and Genetics; University of Genoa; Genoa, Italy
- Laboratory of Experimental Oncology; National Cancer Institute (IST); Genoa, Italy
| | - Nicoletta Castagnino
- Department of Oncology, Biology and Genetics; University of Genoa; Genoa, Italy
- Laboratory of Experimental Oncology; National Cancer Institute (IST); Genoa, Italy
| | - Lorenzo Tortolina
- Department of Oncology, Biology and Genetics; University of Genoa; Genoa, Italy
- Laboratory of Experimental Oncology; National Cancer Institute (IST); Genoa, Italy
| | - Anna Mumot
- Department of Oncology, Biology and Genetics; University of Genoa; Genoa, Italy
- Laboratory of Experimental Oncology; National Cancer Institute (IST); Genoa, Italy
| | | | - Antonio Daga
- Laboratory of Genes Transfer; National Cancer Institute (IST); Genoa, Italy
| | - Michele Cilli
- Animal Facility; National Cancer Institute (IST); Genoa, Italy
| | | | | | - Miriam Perugini
- Department of Internal Medicine; University of Genoa; Genoa, Italy
| | - Gabriele Zoppoli
- Department of Internal Medicine; University of Genoa; Genoa, Italy
| | | | - Raffaele Pesenti
- Department of Applied Mathematics; Ca’ Foscari University; Venice, Italy
| | - Silvio Parodi
- Department of Oncology, Biology and Genetics; University of Genoa; Genoa, Italy
- Laboratory of Experimental Oncology; National Cancer Institute (IST); Genoa, Italy
| |
Collapse
|
6
|
Bagnasco L, Marengo G, Bramardi A, Bovetti B, Merlino G, Rosano S. The medical record as an instrument for monitoring off-label uses and drug related problem: the experience at the Mondovi Hospital. Eur J Hosp Pharm 2012. [DOI: 10.1136/ejhpharm-2012-000074.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
7
|
Bagnasco L, Piras D, Parodi S, Bauer I, Zoppoli G, Patrone F, Ballestrero A. Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors. Curr Cancer Drug Targets 2012; 12:303-15. [DOI: 10.2174/156800912800190929] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2011] [Revised: 06/22/2011] [Accepted: 12/22/2011] [Indexed: 11/22/2022]
|
8
|
Sturla L, Fresia C, Guida L, Grozio A, Vigliarolo T, Mannino E, Millo E, Bagnasco L, Bruzzone S, De Flora A, Zocchi E. Binding of abscisic acid to human LANCL2. Biochem Biophys Res Commun 2011; 415:390-5. [DOI: 10.1016/j.bbrc.2011.10.079] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2011] [Accepted: 10/14/2011] [Indexed: 10/16/2022]
|
9
|
Zoppoli G, Moran E, Soncini D, Cea M, Garuti A, Rocco I, Cirmena G, Grillo V, Bagnasco L, Icardi G, Ansaldi F, Parodi S, Patrone F, Ballestrero A, Nencioni A. Ras-induced resistance to lapatinib is overcome by MEK inhibition. Curr Cancer Drug Targets 2010; 10:168-75. [PMID: 20088787 DOI: 10.2174/156800910791054211] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2009] [Accepted: 12/17/2009] [Indexed: 11/22/2022]
Abstract
Lapatinib, a dual HER2 and EGFR tyrosine kinase inhibitor is highly active in HER2+ breast cancer. However, its efficacy is limited by either primary or acquired resistance. Although mutations in ras genes are rarely found in breast cancer, H-ras overexpression is frequently observed. Moreover, genetic alterations that do not directly involve ras such as Brk amplification, ultimately result in increased ras signaling. Using SKBR3 cells, a HER2+ breast cancer cell line that is naturally devoid of mutations in PI3KCA, PTEN, BRAF, and ras we show that both H-ras overexpression and expression of an oncogenic ras allele (ras V12) reduce susceptibility to lapatinib in analogy to what observed with activating PI3KCA mutations and with a constitutively active form of Akt. Importantly, we found that resistance to lapatinib due to ras overexpression or to ras V12 is overcome by MEK inhibition with U0126, suggesting a key role for the MEK-Erk pathway in ras-induced resistance. Similar results were obtained in BT474 cells, another HER+ breast cancer cell line. Therefore, our data indicate that overexpressed/mutated ras may act as a biological modifier of the response to lapatinib. Combining MEK inhibitors with lapatinib may help overcome this form of resistance and increase the efficacy of lapatinib in these tumors.
Collapse
Affiliation(s)
- Gabriele Zoppoli
- Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Barboro P, D'Arrigo C, Repaci E, Bagnasco L, Orecchia P, Carnemolla B, Patrone E, Balbi C. Proteomic analysis of the nuclear matrix in the early stages of rat liver carcinogenesis: identification of differentially expressed and MAR-binding proteins. Exp Cell Res 2008; 315:226-39. [PMID: 19000672 DOI: 10.1016/j.yexcr.2008.10.017] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2008] [Revised: 09/24/2008] [Accepted: 10/20/2008] [Indexed: 11/19/2022]
Abstract
Tumor progression is characterized by definite changes in the protein composition of the nuclear matrix (NM). The interactions of chromatin with the NM occur via specific DNA sequences called MARs (matrix attachment regions). In the present study, we applied a proteomic approach along with a Southwestern assay to detect both differentially expressed and MAR-binding NM proteins, in persistent hepatocyte nodules (PHN) in respect with normal hepatocytes (NH). In PHN, the NM undergoes changes both in morphology and in protein composition. We detected over 500 protein spots in each two dimensional map and 44 spots were identified. Twenty-three proteins were differentially expressed; among these, 15 spots were under-expressed and 8 spots were over-expressed in PHN compared to NH. These changes were synchronous with several modifications in both NM morphology and the ability of NM proteins to bind nuclear RNA and/or DNA containing MARs sequences. In PHN, we observed a general decrease in the expression of the basic proteins that bound nuclear RNA and the over-expression of two species of Mw 135 kDa and 81 kDa and pI 6.7-7.0 and 6.2-7.4, respectively, which exclusively bind to MARs. These results suggest that the deregulated expression of these species might be related to large-scale chromatin reorganization observed in the process of carcinogenesis by modulating the interaction between MARs and the scaffold structure.
Collapse
Affiliation(s)
- Paola Barboro
- Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi, 10-16132 Genova, Italy
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Ponassi R, Biasotti B, Tomati V, Bruno S, Poggi A, Malacarne D, Cimoli G, Salis A, Pozzi S, Miglino M, Damonte G, Cozzini P, Spyrakis F, Spyraki F, Campanini B, Bagnasco L, Castagnino N, Tortolina L, Mumot A, Frassoni F, Daga A, Cilli M, Piccardi F, Monfardini I, Perugini M, Zoppoli G, D'Arrigo C, Pesenti R, Parodi S. A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity. Cell Cycle 2008; 7:3211-24. [PMID: 18843207 DOI: 10.4161/cc.7.20.6830] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
BH3-only members of the Bcl-2 family exert a fundamental role in apoptosis induction. This work focuses on the development of a novel peptidic molecule based on the BH3 domain of Bim. The antiapoptotic molecule Bcl-X(L), involved in cancer development/progression and tumour resistance to cytotoxic drugs, is a target for Bim. According to a rational study of the structural interactions between wt Bim-BH3 and Bcl-X(L), we replaced specific residues of Bim-BH3 with natural and non-natural aminoacids and added an internalizing sequence, thus increasing dramatically the inhibitory activity of our modified Bim-BH3 peptide, called 072RB. Confocal microscopy and flow cytometry demonstrated cellular uptake and internalization of 072RB, followed by co-localization with mitochondria. Multiparameter flow cytometry demonstrated that the 072RB dose-dependent growth inhibition of leukaemia cell lines was due to apoptotic cell death. No effect was observed when cells were treated with the internalizing vector alone or a mutated control peptide (single aminoacid substitution L94A). Ex-vivo derived leukemic cells from acute myeloid leukaemia (AML) patients underwent cell death when cultured in vitro in the presence of 072RB. Conversely, no significant cytotoxic effect was observed when 072RB was administered to cultures of peripheral blood mononuclear cells, either resting or PHA-stimulated, and bone marrow cells of normal donors. Xenografts of human AML cells in NOD/SCID mice displayed a significant delay of leukemic cell growth upon treatment with 072RB administered intravenously (15 mg/Kg three times, 48 hours after tumour cell injection). Altogether, these observations support the therapeutic potentials of this novel BH3 mimetic.
Collapse
|
12
|
Avignolo C, Bagnasco L, Biasotti B, Melchiori A, Tomati V, Bauer I, Salis A, Chiossone L, Mingari MC, Orecchia P, Carnemolla B, Neri D, Zardi L, Parodi S. Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein. FASEB J 2007; 22:1237-45. [PMID: 18048579 DOI: 10.1096/fj.07-8865com] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
We constructed a single-chain variable fragment miniantibody (G11-scFv) directed toward the transactivation domain of c-Myc, which is fused with the internalization domain Int of Antennapedia at its carboxyl terminus (a cargo-carrier construct). In ELISA experiments, an EC(50) for binding saturation was achieved at concentrations of G11-scFv-Int(-) of approximately 10(-8) M. Internalization of a fluoresceinated Fl-G11-scFv-Int(+) construct was observed in intact human cultured cells with confocal microscopy. After 5 h of incubation in medium containing 1 microM Fl-G11-scFv-Int(+) or Fl-G11-scFv-Int(-), fluorescence intensity was determined in individual cells, both for cytoplasmic and nuclear compartments: concentration levels of Fl-G11-scFv-Int(+), relative to the extracellular culture medium concentration, were 4-5 times higher in the cytoplasm, 7-8 times higher in the nucleus, and 10 times higher in the nucleoli. In the same experimental conditions, the Fl-G11-scFv-Int(-) construct was 3-4 times more concentrated outside of the cells than inside. Cell membranes kept their integrity after 5 h of incubation. The antiproliferative activity of our miniantibody was studied on HCT116 cells. Incubation with 4 microM G11-scFv-Int(+) for 4 days induced very significant statistical and biological growth inhibition, whereas Int alone was completely inactive. Miniantibodies capable of penetrating cell membranes dramatically broaden the potential for innovative therapeutic agents and attack of new targets.
Collapse
Affiliation(s)
- C Avignolo
- Department of Oncology, Biology and Genetics, University of Genoa, L. go R. Benzi 10, Genoa 16132, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Bagnasco L, Tortolina L, Biasotti B, Castagnino N, Ponassi R, Tomati V, Nieddu E, Stier G, Malacarne D, Parodi S. Inhibition of a protein‐protein interaction between INI1 and c‐Myc by small peptidomimetic molecules inspired by Helix‐1 of c‐Myc: identification of a new target of potential antineoplastic interest. FASEB J 2007; 21:1256-63. [PMID: 17215484 DOI: 10.1096/fj.06-7082com] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
c-Myc is a transcription modulator proto-oncogene. When overexpressed, it becomes an important contributor to the multi-hit process of malignant transformation. In two earlier papers in this journal (see refs. 19 , 20) we reported that retro-inverso peptidomimetic molecules inspired by the Helix-1 of c-Myc motif could be sequence-specific antiproliferative agents active in the low micromolar range. We also found that our peptides were not opening the four-alpha-helix Myc:Max bundle. Their antiproliferative activity in cancer cell lines needs the presence of side chains projecting outside of the bundle in the corresponding native H1 motif. This observation suggested interference with an external partner. In this study we investigated the INI1:Myc interaction. INI1 is a subunit of the SWI/SNF complex (component of the enhanceosome surrounding Myc:Max heterodimer). The INI1:Myc interaction was confirmed via pull down, ELISA, and fluorescence anisotropy assays. According to the length of INI1 fragments used, we calculated Kds ranging between 1.3x10(-6) and 4.8x10(-7) M. The three different techniques applied showed that the INI1:Myc interaction was also the target of our retro-inverso peptidomimetic molecules, which seem to bind specifically at INI1. A Myc binding, 21aa INI1 fragment (minimum interacting sequence), could inspire the synthesis of a new class of more selective c-Myc inhibitors.
Collapse
Affiliation(s)
- L Bagnasco
- Department of Oncology, Biology and Genetics, University of Genoa, L. go R. Benzi 10, Genoa 16132, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Nieddu E, Melchiori A, Pescarolo MP, Bagnasco L, Biasotti B, Licheri B, Malacarne D, Tortolina L, Castagnino N, Pasa S, Cimoli G, Avignolo C, Ponassi R, Balbi C, Patrone E, D'arrigo C, Barboro P, Vasile F, Orecchia P, Carnemolla B, Damonte G, Millo E, Palomba D, Fassina G, Mazzei M, Parodi S. Sequence specific peptidomimetic molecules inhibitors of a protein–protein interaction at the helix 1 level of c‐Myc. FASEB J 2005; 19:632-4. [PMID: 15671156 DOI: 10.1096/fj.04-2369fje] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Our work is focused in the broad area of strategies and efforts to inhibit protein-protein interactions. The possible strategies in this field are definitely much more varied than in the case of ATP-pocket inhibitors. In our previous work (10), we reported that a retro-inverso (RI) form of Helix1 (H1) of c-Myc, linked to an RI-internalization sequence arising from the third alpha-helix of Antennapedia (Int) was endowed with an antiproliferative and proapoptotic activity toward the cancer cell lines MCF-7 and HCT-116. The activity apparently was dependent upon the presence of the Myc motif. In this work, by ala-scan mapping of the H1 portion of our molecules with D-aa, we found two amino acids necessary for antiproliferative activity: D-Lys in 4 and D-Arg in 5 (numbers refer to L-forms). In the natural hetero-dimer, these two side chains project to the outside of the four alpha-helix bundle. Moreover, we were able to obtain three peptides more active than the original lead. They strongly reduced cell proliferation and survival (RI-Int-VV-H1-E2A,S6A,F8A; RI-Int-VV-H1-S6A,F8A,R11A; RI-Int-VV-H1-S6A,F8A,Q13A): after 8 days at 10 muM total cell number was approximately 1% of the number of cells initially seeded. In these more potent molecules, the ablated side chains project to the inside in the corresponding natural four alpha-helix bundle. In the present work, we also investigated the behavior of our molecules at the biochemical level. Using both a circular dichroism (CD) and a fluorescence anisotropy approach, we noted that side chains projecting at the interior of the four alpha-helix bundle are needed for inducing the partial unfolding of Myc-H2, without an opening of the leucine zipper. Side chains projecting at the outside are not required for this biochemical effect. However, antiproliferative activity had the opposite requirements: side chains projecting at the outside of the bundle were essential, and, on the contrary, ablation of one side chain at a time projecting at the inside increased rather than decreased biological activity. We conclude that our active molecules probably interfere at the level of a protein-protein interaction between Myc-Max and a third protein of the transcription complex. Finally, CD and nuclear magnetic resonance (NMR) data, plus dynamic simulations, suggest a prevalent random coil conformation of the H1 portion of our molecules, at least in diluted solutions. The introduction of a kink (substitution with proline in positions 5 or 7) led to an important reduction of biological activity. We have also synthesized a longer peptido-mimetic molecule (RI-Int-H1-S6A,F8A-loop-H2) with the intent of obtaining a wider zone of interaction and a stronger interference at the level of the higher-order structure (enhanceosome). RI-Int-H1-S6A,F8A-loop-H2 was less active rather than more active in respect to RI-Int-VV-H1-S6A,F8A, apparently because it has a clear bent to form a beta-sheet (CD and NMR data).
Collapse
Affiliation(s)
- Erika Nieddu
- Department of Pharmaceutical Sciences, University of Genoa, Viale Benedetto XV, Genoa 16132, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Cimoli G, Bagnasco L, Pescarolo MP, Avignolo C, Melchiori A, Pasa S, Biasotti B, Taningher M, Parodi S. Signaling proteins as innovative targets for antineoplastic therapy: our experience with the signaling protein c-myc. Tumori 2001; 87:S20-3. [PMID: 11989613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Affiliation(s)
- G Cimoli
- Department of Oncology Biology and Genetics, University of Genoa, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Pescarolo MP, Bagnasco L, Malacarne D, Melchiori A, Valente P, Millo E, Bruno S, Basso S, Parodi S. A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems. FASEB J 2001; 15:31-33. [PMID: 11099487 DOI: 10.1096/fj.00-0422fje] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
In 1998 we reported that an L-peptide derived from H1 of c-Myc (Int-H1-S6A,F8A), linked to an internalization sequence from the third a-helix of Antennapedia, was endowed with an antiproliferative and proapoptotic activity toward a human mammary cancer cell line: The activity apparently depends upon the presence of the Myc motif. In the present work we have added new dimensions to our original findings. It is known that short retro-inverso (RI-) peptides can assume a 3D conformation very close to their corresponding L-forms and can be recognized by the same monoclonal antibody. We synthesized a RI-peptide form of our original L-peptide: It was much more resistant to serum peptidases than the original molecule (a half life of days rather than hours); in addition, the RI-form of the original Antennapedia internalization sequence was perfectly capable of carrying a D-peptide into human cells. We have studied three different potentially active peptides. L-peptides: Int-H1wt, Int-H1-S6A,F8A. D-peptides: RI-Int -H1-S6A,F8A. We have also studied three presumed control peptides: Int and RI-Int (no H1 motif), H1-S6A,F8A (no internalization sequence). Both 'active' and 'control' peptides have essentially confirmed our expectations, however, in cells treated with the higher concentration (10 mM) of the control peptide RI-Int, non-Myc related side effects could be detected. In order to investigate whether the antiproliferative activities displayed by some of our molecules were indeed related to an interference with the role of c-Myc (and molecules of the family), we chose an iso-amphipathic modified peptide of the H1 motif, with a proximity coefficient >50% and where the major change was at position 7 (F-->A). From a family of 73 H1 motifs belonging to (H1-Loop-H2) hu man sequences, the smallest evolutionary distance from our reference peptide was observed for the H1 of N-Myc, L-Myc, c-Myc, H1-S6A,F8A of c-Myc, and Max, in that order. Our reference peptide was therefore appropriate as a check of whether we were indeed observing activities related to Myc functions. Both Int-H1isoamph and the corresponding RI-Int-H1isoamph peptide were synthesized and studied. In terms of biological targets, we added to the human mammary cancer line of our previous work (MCF-7 cells) a colon cancer line (HCT-116 cells) and also a system of normal cells: human peripheral blood lymphocytes (PBLs) stimulated with phytohemoagglutinin (PHA). Peptides carrying an iso-amphipathic-modified H1 sequence were always very clearly (3-10 times) less active than the corresponding peptides carrying a conserved "H1 of Myc" motif. This finding was noted in five independent situations (all the cellular models considered at the present time): MCF-7 cells treated with L-peptides; MCF-7 cells treated with RI-peptides; HCT-116 cells treated with L-peptides; PBLs treated with L-peptides; PBLs treated with RI-peptides. Modulation of transcription levels of ornithine decarboxylase (ODC), p53, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), in PBLs treated with our different molecules, was well compatible with an interference by our active peptides at the level of Myc transcriptional activity. We had already reported a similar observation in MCF-7 cells. On a molar basis, RI-peptides were about 5-10 times more potent and 30-35 times more stable in complete culture medium, than their corresponding L-forms. RI-Int can probably internalize longer peptido-mimetic molecules (for instance molecules mimetic of (H1-Loop-H2), or even more. These possibilities open the way to rodent studies and to more potent/selective Myc inhibitors-two steps closer to a potential drug.
Collapse
Affiliation(s)
- M P Pescarolo
- Laboratory of Experimental Oncology, National Institute for Cancer Research, 16132 Genoa, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Giorello L, Clerico L, Pescarolo MP, Vikhanskaya F, Salmona M, Colella G, Bruno S, Mancuso T, Bagnasco L, Russo P, Parodi S. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res 1998; 58:3654-9. [PMID: 9721875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
c-Myc is a nuclear protein with important roles in cell transformation, cell proliferation, and gene transcription. It has been previously shown that a 14-amino acid (aa) modified peptide (H1-S6A,F8A) derived from the helix 1 (H1) carboxylic region of c-Myc can interfere in vitro with specific c-Myc DNA binding. Here, we have linked the above Myc-derived 14-aa peptide to a 16-aa sequence from the third helix of Antennapedia (Int). It has been repeatedly reported that this 16-aa Antennapedia peptide is able to cross mammalian cell membranes and to work as a vector for short peptides. Using fluorescent (dansylated or rhodaminated) peptides, we have shown that the fusion peptide with the Antennapedia fragment (Int-H1-S6A,F8A) but not the c-Myc derived fragment alone (H1-S6A,F8A) was capable of internalization inside MCF-7 human breast cancer cells. Int-H1-S6A,F8A and H1-S6A,F8A were the only two peptides capable of inhibiting coimmunoprecipitation of the c-Myc/Max heterodimer in vitro. We have treated (continuously for 10-11 days) MCF-7 cells with four different peptides: Int, H1-S6A,F8A, Int-H1-S6A,F8A, and Int-H1wt [a peptide differing from Int-H1-S6A,F8A by 2 aa (S6 and F8) in the H1 region]. In intact MCF-7 cells, Int-H1-S6A,F8A was the only active peptide capable of inducing the following biological effects: (a) inhibition of cloning efficiency on plates; (b) inhibition of cell growth and induction of apoptosis in subconfluent/confluent cells; and (c) inhibition of transcription of two c-Myc-regulated genes (ODC and p53). Int-H1-S6A,F8A was active in the 1-10 microM range. Int-H1-S6A,F8A may represent a lead molecule for peptidomimetic compounds that have a similar three-dimensional structure but are more resistant to peptidases and, therefore, suitable for in vivo treatment of experimentally induced tumors.
Collapse
Affiliation(s)
- L Giorello
- Department of Experimental Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Sacco MG, Gribaldo L, Barbieri O, Turchi G, Zucchi I, Collotta A, Bagnasco L, Barone D, Montagna C, Villa A, Marafante E, Vezzoni P. Establishment and characterization of a new mammary adenocarcinoma cell line derived from MMTV neu transgenic mice. Breast Cancer Res Treat 1998; 47:171-80. [PMID: 9497105 DOI: 10.1023/a:1005988715285] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
A new murine cell line, named MG1361, was established from mammary adenocarcinomas arising in a MMTV-neu transgenic mouse lineage where breast tumors develop in 100% of females, due to the overexpression of the activated rat neu oncogene in the mammary gland. The MG1361 cell line shows an epithelial-like morphology, has a poor plating efficiency, low clonogenic capacity, and a doubling time of 23.8 hours. Karyotype and flow cytometry analysis revealed a hypotetraploid number of chromosomes, whereas cell cycle analysis showed 31.2% of cells to be in the G1 phase, 21.4% in S and 47.4% in G2 + M. This cell line maintains a high level of neu expression in vitro. The MG1361 cell line was tumorigenic when inoculated in immunodeficient (nude) mice and the derived tumors showed the same histological features as the primary tumors from which they were isolated. MG1361 cells were positive for specific ER and PgR binding which was competed by tamoxifen, making this cell line useful for the evaluation of endocrine therapy. Moreover, they were sensitive to etoposide treatment, suggesting that they could be a model for the study of chemotherapy-induced apoptosis. As the tumors arising in MMTV-neu transgenic mice have many features in common with human mammary adenocarcinomas (Sacco et al., Gene Therapy 1995; 2: 493-497), this cell line can be utilized to perform basic studies on the role of the neu oncogene in the maintenance of the transformed phenotype, and to test novel protocols of therapeutic strategies.
Collapse
Affiliation(s)
- M G Sacco
- Istituto di Tecnologie Biomediche Avanzate, CNR, Milano, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Sacco MG, Zecca L, Bagnasco L, Chiesa G, Parolini C, Bromley P, Catò EM, Roncucci R, Clerici LA, Vezzoni P. A transgenic mouse model for the detection of cellular stress induced by toxic inorganic compounds. Nat Biotechnol 1997; 15:1392-7. [PMID: 9415893 DOI: 10.1038/nbt1297-1392] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Transgenic mice for genotoxicity testing have been developed, although no such models have been produced for the evaluation of toxic, nongenotoxic chemical compounds. We have developed a transgenic mouse model for the analysis of toxic inorganic compounds. We engineered a mouse lineage with the human growth hormone (hGH) gene under the control of the human hsp70 promoter, in which a plasma-detectable hGH response can be elicited by exposure to heat shock. In primary cell cultures from these mice, hGH release was observed following treatment with several toxic inorganics. Transgenic mice injected intraperitoneally with sodium arsenite, cadmium chloride, copper sulphate, or methylmercurium chloride showed significant hGH levels in plasma.
Collapse
Affiliation(s)
- M G Sacco
- Institute of Advanced Biomedical Technologies, National Research Council, Milan, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
Four genes were mapped to the Xq24-25 region by searching the EST and the non-redundant database with short tracts of genomic sequences. These were random STSs present in the STS database or sequences derived from CpG islands (EagI-based STSs). One of the four matches corresponded to the full length transcript from the intronless glutamate dehydrogenase gene. The second was the human homolog of the bovine NADH ubiquinone oxidoreductase MWFE subunit gene (GDB symbol: NDUFA1). The other two, ZNF183 and ITBA4, were novel genes whose function cannot directly be inferred from their sequence analysis. However, a known motif, the C3HC4 Ring finger domain, shared by various tumor suppressors, DNA repair genes and cytokine receptor-associated molecules, is present at the C terminus of the ubiquitously expressed ZNF183 gene. ITBA4 is expressed at various levels in different tissues and is alternatively processed in brain. Similarity search did not detect any significant match in databases. These results, together with others previously reported by our laboratory, suggest that comparison of genomic and transcribed sequences which are continuously accumulating in databases, can provide 'virtual' mapping of a substantial number of ESTs to the specific genomic region which the STSs have been derived from.
Collapse
Affiliation(s)
- A Frattini
- Istituto di Tecnologie Biomediche Avanzate, Consiglio Nazionale delle Ricerche, Milan, Italy.
| | | | | | | | | | | | | |
Collapse
|
21
|
Sacco MG, Benedetti S, Duflot-Dancer A, Mesnil M, Bagnasco L, Strina D, Fasolo V, Villa A, Macchi P, Faranda S, Vezzoni P, Finocchiaro G. Partial regression, yet incomplete eradication of mammary tumors in transgenic mice by retrovirally mediated HSVtk transfer 'in vivo'. Gene Ther 1996; 3:1151-6. [PMID: 8986442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Mice transgenic for the activated rat neu oncogene under the control of the mouse mammary tumor virus long terminal repeat (MMTV-LTR) (neu+ mice), develop breast tumors in 100% of cases. We have previously reported that double transgenic mice obtained from crossing neu+ mice with mice transgenic for the herpes simplex virus thymidine kinase (HSVtk) gene can be used as a suitable model to test the 'suicide gene' strategy for mammary tumor gene therapy in vivo. In the present study, we evaluated the efficacy of the HSVtk/ganciclovir (GCV) system in the neu+ mice by inoculating cells producing a retroviral vector bearing the HSVtk gene in the mammary tumors on one side of the animals, and comparing their weight with that of the contralateral tumors, after systemic GCV administration. A statistically significant effect of this therapy was clearly seen (P < 0.001) but complete eradication of the tumors could not be achieved. This was not due to the inefficient delivery of GCV, as no HSVtk expression was detected in the residual tumors, but could be related to the low transduction efficiency (< 10%) and to inability of the 'bystander effect' (probably due to the absence of functional gap-junctions among mammary tumor cells) to kill nontransduced neoplastic cells. These data suggest that results obtained by in vivo models using transplanted tumor cell lines as targets for gene therapy might not be immediately transferable to spontaneously arising tumors in animals or humans.
Collapse
Affiliation(s)
- M G Sacco
- Istituto di Tecnologie Biomediche Avanzate, CNR, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Corti A, Merli S, Bagnasco L, D'Ambrosio F, Marino M, Cassani G. Identification of two forms (31-33 and 48 kD) of the urinary soluble p55 tumor necrosis factor receptor that are differentially N- and O-glycosylated. J Interferon Cytokine Res 1995; 15:143-52. [PMID: 8590318 DOI: 10.1089/jir.1995.15.143] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
The structure and the activity of urinary soluble TNF receptor type 1 (sTNF-R1), isolated from the urine of normal individuals, has been characterized and compared with that of recombinant sTNF-R1 expressed in CHO cells and with that of a nonglycosylated form expressed in Escherichia coli. Urinary sTNF-R1 was resolved in a major band of 31-33 kD and in a 48 kD band (less than 5% of total) by reducing SDS-PAGE; CHO sTNF-R1 was resolved in two bands of 29 and 31 kD. All bands were recognized by various anti-sTNF-R1 antibodies as well as by TNF-alpha in western and ligand blotting assays. No cross-reaction was observed with anti-TNF-R2 antibodies. N- and O-glycosylation studies indicated that (1) the 29-31 kD recombinant form as well as the 31-33 kD urinary form are N-glycosylated; (2) the differences between the 29-31 and 31-33 kD recombinant and natural products are mainly related to differences in the N-linked sugar content; and (3) the 48 kD sTNF-R1 isolated from urine also contains O-linked sugars. The urinary sTNF-R1 antigen mixture was able to inhibit TNF-alpha cytotoxicity with a potency comparable to that of nonglycosylated E. coli sTNF-R1. At variance, urinary sTNF-R1 was able to inhibit TNF-beta sevenfold more efficiently than E. coli sTNF-R1. In conclusion, two subtypes of sTNF-R1 have been isolated from urine: a main N-glycosylated form of 31-33 kD and a N- and O-glycosylated form of 48 kD that appears to be a minor constituent of the urinary sTNF-R1 antigen.
Collapse
MESH Headings
- Animals
- Antigens, CD/chemistry
- Antigens, CD/immunology
- Blotting, Western
- CHO Cells
- Cells, Cultured
- Cricetinae
- Cytotoxicity Tests, Immunologic
- Electrophoresis, Polyacrylamide Gel
- Escherichia coli/chemistry
- Glycosylation
- Humans
- Lymphotoxin-alpha/immunology
- Mice
- Nitrogen/metabolism
- Oxygen/metabolism
- Receptors, Tumor Necrosis Factor/chemistry
- Receptors, Tumor Necrosis Factor/immunology
- Receptors, Tumor Necrosis Factor, Type I
- Recombinant Proteins/chemistry
- Recombinant Proteins/immunology
- Tumor Necrosis Factor-alpha/immunology
- Urine/chemistry
Collapse
Affiliation(s)
- A Corti
- Molecular Immunology and Biochemistry Unit, Tecnogen ScpA, Piana di Monte Verna, Italy
| | | | | | | | | | | |
Collapse
|
23
|
Corti A, Bagnasco L, Cassani G. Identification of an epitope of tumor necrosis factor (TNF)-receptor type 1 (p55) recognized by a TNF-alpha-antagonist monoclonal antibody. Lymphokine Cytokine Res 1994; 13:183-90. [PMID: 7524695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The relationships between epitope topography and agonistic/antagonistic effects of anti-TNF receptor type 1 (TNF-R1) antibodies on TNF-alpha cytotoxic activity have been studied. To this purpose various monoclonal antibodies (mAbs) against the soluble form of TNF-R1 (sTNF-R1) have been generated and characterized. Epitope topography studies identified at least four distinct epitopes located outside (4E10) or within (or close to) the TNF-alpha binding site of urinary sTNF-R1 (7H3, 4C1, 9B11). mAbs 7H3 and 4C1 were able to neutralize the inhibition of human TNF-alpha cytotoxicity on L-M cells by sTNF-R1, while 4E10 was unable. Moreover, 7H3 and 4C1 were able to antagonize the TNF-alpha cytotoxicity on human U937 cells, while they were uneffective on mouse L-M cells, suggesting that these antibodies recognize, in a species-specific mode, also the membrane form of the human receptor. No agonistic effects were observed when these antibodies were used in the absence of TNF-alpha. Epitope topography studies carried out using overlapping decapeptides covering most of the sTNF-R1 sequence showed that residues 143-148 of the fourth cysteine-rich domain of the receptor (FFLREN) contain antigenic determinants recognized by the antagonist antibody 7H3. These results suggest that at least part of residues 143-148 of sTNF-R1 are surface exposed on the soluble as well as on the membrane forms of TNF-R1 and are accessible to TNF-alpha antagonists.
Collapse
Affiliation(s)
- A Corti
- Molecular Immunology and Biochemistry Unit, Tecnogen ScpA, Milan, Italy
| | | | | |
Collapse
|